RituximabÒ (MabThera; Rituxan Roche) is a chimeric human/ murine immunoglobulin G1 monoclonal antibody that binds specifically to the B-cell-surface antigen, CD20. Using the combination of CHOP-R leads to significant improvement in the outcome of elderly patients with diffuse large B-cell lymphoma, with significant survival benefits maintained during a 5-year follow-up [1] .
Other studies have been conducted in patients with follicular lymphoma or mantle-cell lymphoma and have shown the same benefits for the combination of rituximab plus chemotherapy [2] .
In general, rituximab is a well-tolerated medicine, although a specific infusion rate a given number of hours is recommended to avoid reactions derived from the liberation of cytokines. This syndrome can cause severe dyspnoea, bronchospasm, fever, urticaria and angio-oedema and can share with tumour lysis syndrome some characteristic such as hyperuricaemia, hypocalcaemia, hyperkalaemia and severe acute respiratory insufficiency.
All of this indicates that one of the most severe problems regarding the administration of rituximab is either the overload faced by outpatient clinics or else the need to go ahead with the admission of the patient for a treatment that can take hours.
In our clinical practice we have observed the good tolerance of infusions administered faster and with the absence of subsequent adverse secondary effects. For this, we designed a study to determine the tolerance and the immediate complications of a series of patients treated prospectively, consecutively, and nonselectively with a constant infusion rate of rituximab in one hour after the first cycle.
We studied all patients diagnosed with diffuse large-B-cell lymphoma who were receiving subsidiary treatment with rituximab either in monotherapy or associated with chemotherapy.
In the first cycle, the administration of the rituximab at a dose of 375 mg/m 2 body surface area (BSA) follows the habitual guidelines for the infusion rate, according to the laboratory's technical index. Thus, the initial infusion rate is 50 mg/hour; and, after the first 30 minutes, can be increased in increments of 50 mg/hour every 30 minutes, up to a maximum of 400 mg/hour. The premedication was given with 1 g of intravenous paracetamol and 5 mg of oral dexchlorpheniramine, in addition to the steroids recommended by each therapeutic protocol. If during this infusion no tolerance problems occurred, the next cycle and the successive ones after it were given to the patient on an outpatient basis, with the same premedication and with a constant infusion rate of 1 hour. Toxic effects were assessed according to the Common Toxicity Criteria of the National Cancer Institute (version 3.0).
From January 2003 to September 2005, 40 patients with Hodgkin's and non-Hodgkin's lymphoma were treated with rituximab-based chemotherapy with a total of 233 infusions, with an average of 5.8 infusions per patient. The first infusion was given in 5 hours on average (range between 3 hours and 6 hours and 30 minutes). All patients received more than three infusions, with the exception of 1 patient, who died because of tumoral progression after the second infusion. All the infusions subsequent to the first were given in 1 hour. Even in those patients who during the first infusion showed some hypersensitivity reaction that made this infusion rate decrease, the subsequent infusions could be given in 1 hour without relevant problems. The only toxicity of the infusions in 1 hour were: fever in 1 patient, chills in 2 patients and limited cutaneous reaction with rash in 2 patients, all of these grade 1, which comprises 0.017% of problems during the 1-hour infusions.
The majority of these problems were diffuse large-B-cell lymphoma 60% and in first line of treatment (83%), with an average age of 63 years, although patients up to 87 years of age were treated. Table 1 presents baseline characteristics. Twenty-one patients presented with voluminous disease. The antibody induces lymphoma cell lysis via different immunologic or direct mechanism, complement-mediated histolysis, antibody-dependent cell cytotoxicity, and induction of apoptosis, and acts synergistically with chemotherapy [3, 4] .
Rituximab is well tolerated and did not add toxicity to the CHOP [5] . In our experience, a 1-h infusion is safe and free of complications, even in those patients who had required a slow-down of the first infusion, in the next infusions could be applied in 1 hour without relevant problems. Nor was the presence of voluminous mass, present in 52% of our patients, or advanced age, with eight patients older than 75, and two older than 80, predictive of less tolerance to this rate of infusion.
We believe that in those patients who, during the first infusion, showed no hypersensitivity reaction, the subsequent infusions can be given at a faster rate. In spite of the fact that a limited number of patients was treated, the number of infusions is high (233); thus, we believe that the sample is representative and with sufficient confidence margin to guarantee the security of this guideline. The majority of our patients were treated with CHOP-R or CHOP-like, and while we cannot have the same degree of innocuousness for other ESHAP type combinations, which was received by only a single patient, we believe that this rate can be used in other therapeutic schemes without compromise, so long as an adequate pre-medication is done.
We know of no other publication that discusses rapidinfusion rituximab aside from a single abstract which reports infusions of 90 minutes with excellent tolerance [6] .
We believe that this proposal for a change of infusion rate is very important because it greatly reduces the many hours of hospitalization for patients and consequently amounts to more cost-effective treatment. 
